Aspirin for preventing the recurrence of venous thromboembolism.

Détails

ID Serval
serval:BIB_42E530ECCC83
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Aspirin for preventing the recurrence of venous thromboembolism.
Périodique
New England Journal of Medicine
Auteur(s)
Becattini C., Agnelli G., Schenone A., Eichinger S., Bucherini E., Silingardi M., Bianchi M., Moia M., Ageno W., Vandelli M.R., Grandone E., Prandoni P.
Collaborateur(s)
WARFASA Investigators
Contributeur(s)
Agnelli G., Becattini C., Prandoni P., Becattini C., Agnelli G., Prandoni P., Ageno W., Cimminiello C., Eichinger S., Duranti M., Radicchia S., Guercini F., Vedovati MC., Tormene D., Perlati M., Barbar S., Poggio R., Leischer L., Bucherini E., Galimberti D., Leone MF., Beretta A., Carugati A., Braham S., Romualdi E., Tiscia G., Colaizzo D., Grilli M., Siragusa S., Salvi R., Miccio M., Ria L., Zanatta N., Poli D., Camporese G., Verlato F., Salvi A., Nitti C., Santi R., Cimminiello C., Scannapieco G., Barillari G., Pasca S., De Gaudenzi E., Cappelli R., Di Minno G., Tufano A., Frausini G., Bova C., Pogliani E., Signorelli SS., Testa S., Alatri A., Mancuso G., Grifoni S., Lodigiani C.
ISSN
1533-4406 (Electronic)
ISSN-L
0028-4793
Statut éditorial
Publié
Date de publication
2012
Volume
366
Numéro
21
Pages
1959-1967
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
BACKGROUND: About 20% of patients with unprovoked venous thromboembolism have a recurrence within 2 years after the withdrawal of oral anticoagulant therapy. Extending anticoagulation prevents recurrences but is associated with increased bleeding. The benefit of aspirin for the prevention of recurrent venous thromboembolism is unknown.
METHODS: In this multicenter, investigator-initiated, double-blind study, patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment were randomly assigned to aspirin, 100 mg daily, or placebo for 2 years, with the option of extending the study treatment. The primary efficacy outcome was recurrence of venous thromboembolism, and major bleeding was the primary safety outcome.
RESULTS: Venous thromboembolism recurred in 28 of the 205 patients who received aspirin and in 43 of the 197 patients who received placebo (6.6% vs. 11.2% per year; hazard ratio, 0.58; 95% confidence interval [CI], 0.36 to 0.93) (median study period, 24.6 months). During a median treatment period of 23.9 months, 23 patients taking aspirin and 39 taking placebo had a recurrence (5.9% vs. 11.0% per year; hazard ratio, 0.55; 95% CI, 0.33 to 0.92). One patient in each treatment group had a major bleeding episode. Adverse events were similar in the two groups.
CONCLUSIONS: Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding. (Funded by the University of Perugia and others; WARFASA ClinicalTrials.gov number, NCT00222677.).
Mots-clé
Aged, Anticoagulants/therapeutic use, Aspirin/adverse effects, Aspirin/therapeutic use, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage/chemically induced, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors/adverse effects, Platelet Aggregation Inhibitors/therapeutic use, Pulmonary Embolism/prevention & control, Recurrence/prevention & control, Secondary Prevention, Venous Thromboembolism/drug therapy, Venous Thromboembolism/prevention & control, Venous Thrombosis/prevention & control, Vitamin K/antagonists & inhibitors
Pubmed
Web of science
Création de la notice
14/02/2013 13:32
Dernière modification de la notice
03/03/2018 16:39
Données d'usage